Rapid Reviews in Cardiology® - June 2022

Women show significantly lower risk of first, recurrent life-threatening VTA events than men, while it is more pronounced in patients with NICM.

Rivaroxaban monotherapy was associated with a 38% lower risk of total cardiovascular and bleeding events.

The HTRA1 and CFH risk alleles, family history of AMD, the LOC387715 risk allele, and cardiovascular disease were all linked to an increased risk of AMD.

Investigators contribute more detailed understanding of the association between sleeping disorder and cardiovascular event risks.

New post hoc data from the STEP 1 and 4 trials show an approximate 60% risk reduction of type 2 diabetes over 10 years versus placebo.